Session: 102. Iron Homeostasis and Biology: Poster I
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Maternal Health
Unrelated to pregnancy, hormones estrogen and prolactin have been previously implicated in hepcidin regulation2,3, although with conflicting results on the direction of hepcidin change4-6. The levels of both hormones increase dramatically over the course of pregnancy, thus we hypothesized that they may modulate iron homeostasis during pregnancy. Studying the role of estrogens and prolactin during pregnancy is challenging as both hormones are required for pregnancy. Additionally, mice with global knockout (KO) of either estrogen receptor alpha or prolactin receptor are infertile. Thus, to determine the contribution of estrogens and prolactin on maternal hepcidin suppression during pregnancy, we generated liver-specific knockouts of either estrogen receptor alpha (Er-αf/f;Alb-Cre+) or prolactin receptor (Prlrf/f;Alb-Cre+), here abbreviated as ER-α KO and PRLR KO. Female ER-α KO, PRLR KO and WT mice were set up for timed pregnancy, and liver hepcidin mRNA, as well as maternal and embryo iron and hematological parameters were measured at E18.5 . Hepcidin suppression in ER-α KO and PRLR KO dams was not different from that in WT dams, suggesting that estrogens and prolactin are not major mediators of maternal hepcidin suppression. Additionally, maternal and embryo hematological parameters and liver iron concentrations were similar between WT, ER-α KO, PRLR KO pregnancies, further supporting our observation that estrogens and prolactin do not regulate iron homeostasis in pregnancy. The mechanisms by which maternal hepcidin is suppressed during pregnancy remain to be determined.
1Sangkhae V et al, Blood, 2020
2Yang Q et al, Endocrinology, 2012
3Wang J et al, Nanomedicine: nanotechnology, biology and medicine, 2015
4Zhen et al, Hepatology, 2013
5Ikeda Y et al, PloS one, 2012
Disclosures: Ganz: Intrinsic LifeSciences: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Silarus Therapeutics: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Ionis Pharmaceuticals: Consultancy; Disc Medicine: Consultancy. Nemeth: Disc Medicine: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Ionis Pharma: Consultancy; Protagonist Pharma: Consultancy; Intrinsic LifeSciences: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Vifor Pharma: Consultancy; Silarus Pharma: Consultancy, Current holder of stock options in a privately-held company; AstraZeneca and Fibrogen: Consultancy; Chiesi: Consultancy; Chugai: Consultancy; GSK: Consultancy; Novo Nordisk: Consultancy.